.jpg)
The great experience gained in the development of Calprest and calprest NG ( Calprotectin in Elisa) allowed Eurospital to contrive a new generation of rapid test comparable to the traditional ELISA assay, designing an innovative system able to detect callprotectin in stool in a wide range (50-1005 mg/kg). Calprotectin concentration is sometimes very high and cannot be quantitative detected by other kits. The calfast XT wide range of quantification leads to the possibility to use it for patient treatment follow up and to have quantitative results without additional and further dillutions.
Calfast XT is a rapid assay and provides with quantitative result of calprotectin concentration in stool by means of the dedicated calfast reader. controls are included in order to supply to laboratories an effective tool for internal control.
In a few minutes Calfast XT provides with faecal concentration of calprotectin using lateral flow technology applied to a support on which the sample is dispensed the coloured band resulting in the card will be detected and quantified by a dedicated reader (calfast Reader). the calfast reader uses a lot specific calibration curve to calculate the calprotection concentration. Nonetheless the detectable range of calprotectin is between 15 and 100mg/kg, the calprotectin values obtained by calfast reader will be expressed as reported in the following Table
Download Brochure
The new reference ELISA test for the in vitro diagnosis of inflammatory Bowel Disorders (IBD) quantitative non invasive method for the determination of calprotectin in stool by means of an extended calibtation curve.
Crohn's disease(CD) and ulcerous colities(UC) are chronic inflammatory bowel diseases(IBD) with unknown aetilogy. their prevalence is extremely variable in the different case studies:about 40/100.000 for CD and 100/100.000 for UC .The annual incidence rate is about 4/100,000 inhabitant for CD and 8/100,000 for UC. Colorectal caner (CRC), whose know main risk factors are genetic predisposition, diel, presence of IBD and age, has an yearly rate incidence of 25/100.000 in western europe and USA populations.
In association with clinical findings, Calprest NG can be used for the in vitro diagnosis, folow-up and treatment monitoring of patients affected by inflammatory Bowel Disease(IBD), Irritable Bowel Syndrome as well as for screening and surveillance of high risk CRC patients.
calprotectin belongs to the group of Ca-binding proteins of the S100 family and is present in lange amounts in neutrophilic granulocytes, where it accounts for 5% of total proteins and 60% of the proteins of the cytoplasmatic protion. the increase of faecal calprotectin appears to be due to faecal calprotectin appeas to be due to faecal excretion of neutrophils and macrophages migrated from the blood stream into the intestinal lumen through the inflamed mucosa. A strict correlation has been demonstrated between the calprotective levels and the clinical indexes of disease activity in patient with IBD.